EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cost, Cost-effectiveness and Survival Impact Assessment for A Better Management of Colorectal Cancer Patients: A Single Centre Comprehensive Analysis

Adrian Ionut Gana, Cecilia Bica, Cristina Alexandra Ciocan, Elena Ofelia Moșteanu, Teodora Atena Pop, Ioana Berindan-Neagoe, Ioan Cătălin Vlad, Patriciu Andrei Achimaș-Cadariu

Journal of Gastrointestinal and Liver Diseases · 2024

DOI: 10.15403/jgld-5796 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastrointestinal and Liver Diseases, 2024. Verfasst von Adrian Ionut Gana und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. . ionut.gana@medevents.ro. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Colorectal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims: The world healthcare systems are currently challenged by the accumulating burden of colorectal cancer (CRC), and cancer registries represent an important segment for prevention and developing management plans, being useful in providing data regarding incidence, mortality, survival, exposure to carcinogens, lifestyle. Retrospective data from CRC patients in Romania was used to assess survival impact, costs, and cost-effectiveness considering three crucial aspects: pharmacology, chemo-/radio-therapy, and hospitalization for care and management of these patients.

Methods

423 CRC patients from the Institutional Cancer Registry of the Prof. Dr. Ion Chiricuta Institute of Oncology in Cluj-Napoca, Romania were included in the cost analysis. For the assessment of cost efficiency of the primary treatment strategy, we collected data regarding direct medical costs associated with surgery, radiotherapy and medication, as well as the afferent day or continuous hospitalization, for each patient. For the cost-effectiveness analysis we used the method of estimation of incremental cost-effectiveness ratio.

Results

No compelling differences regarding survival time were observed in different therapeutic options per CRC stage. Substantial differences in cost effectiveness among therapeutic options in the same stage of several thousand Euros in stages I-III, while for stage IV, the ICER was more than 100,000 Euros per life saved.

Conclusions

Systematic evaluation of costs, cost-effectiveness, and survival impact, helps healthcare systems can make informed decisions to improve the management of colorectal cancer patients, optimizing outcomes while minimizing financial burden.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisColorectal NeoplasmsHumansRomaniaRetrospective StudiesMaleFemaleAgedMiddle AgedRegistriesNeoplasm StagingHealth Care CostsTime FactorsTreatment OutcomeDrug CostsHospitalization

Autor:innen und Institutionen

  • Department of Oncology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. . ionut.gana@medevents.ro.
  • Research Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.. . cecilia.bica8@gmail.com.
  • Research Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.. cristina.ciocan@umfcluj.ro.
  • Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca, Romania; Regional Institute of Gastroenterology and Hepatologie "Prof. dr. Octavian Fodor" Cluj-Napoca, Romania. ofeliamo…
  • Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca, Romania; Regional Institute of Gastroenterology and Hepatologie "Prof. dr. Octavian Fodor" Cluj-Napoca, Romania. teodorap…
  • Research Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania;. ioana.neagoe@umfcluj.ro.

Zitieren

APA

Gana, A. I., Bica, C., Ciocan, C. A., Moșteanu, E. O., Pop, T. A., Berindan-Neagoe, I., Vlad, I. C., & Achimaș-Cadariu, P. A. (2024). Cost, Cost-effectiveness and Survival Impact Assessment for A Better Management of Colorectal Cancer Patients: A Single Centre Comprehensive Analysis. Journal of Gastrointestinal and Liver Diseases. https://doi.org/10.15403/jgld-5796

Vancouver

Gana AI, Bica C, Ciocan CA, Moșteanu EO, Pop TA, Berindan-Neagoe I, et al. Cost, Cost-effectiveness and Survival Impact Assessment for A Better Management of Colorectal Cancer Patients: A Single Centre Comprehensive Analysis. Journal of Gastrointestinal and Liver Diseases. 2024. doi:10.15403/jgld-5796

BibTeX
@article{Gana2024,
  author = {Gana, Adrian Ionut and Bica, Cecilia and Ciocan, Cristina Alexandra and Moșteanu, Elena Ofelia and Pop, Teodora Atena and Berindan-Neagoe, Ioana and Vlad, Ioan Cătălin and Achimaș-Cadariu, Patriciu Andrei},
  title = {Cost, Cost-effectiveness and Survival Impact Assessment for A Better Management of Colorectal Cancer Patients: A Single Centre Comprehensive Analysis},
  journal = {Journal of Gastrointestinal and Liver Diseases},
  year = {2024},
  doi = {10.15403/jgld-5796}
}
Kostenlos starten →